
Opinion|Videos|January 8, 2025
APOC3 Inhibitors
Key Takeaways
- Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
- Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Panelists discuss important novel therapies emerging for familial chylomicronemia syndrome (FCS), focusing on APOC3 inhibitors, including small interfering RNA (siRNA) and antisense oligonucleotides (ASO), and their potential to address the underlying lipid metabolism dysfunction in patients with FCS.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Can you review important novel therapies for FCS that are APOC3 inhibitors (siRNA and ASO) that have recently emerged?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
FDA Accepts NDA for Ralinepag in Pulmonary Arterial Hypertension
2
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
3
Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD
4
How VISIONARY's Design Targets APRIL in IgA Nephropathy, With Dana Rizk, MD
5



































































